Loading
Vienna oncologist who led TUXEDO-1, the small trial that showed trastuzumab deruxtecan can shrink active brain metastases from HER2-positive breast cancer.
Rupert Bartsch is a medical oncologist at the Medical University of Vienna who focuses on brain metastases from breast cancer. He was first author of the 2022 Nature Medicine report of TUXEDO-1, a single-arm phase 2 trial in which trastuzumab deruxtecan produced intracranial responses in most patients with active brain metastases from HER2-positive breast cancer, evidence that the antibody-drug conjugate works in the brain.
| Title | Journal | Year |
|---|---|---|
| TUXEDO-1: trastuzumab deruxtecan in HER2-positive breast cancer with active brain metastases | Nature Medicine | 2022 |
Shares HER2-positive breast cancer with brain metastases, HER2-positive breast cancer, Breast cancer (all types) and the tags breast, trialist.
Shares HER2-positive breast cancer, Breast cancer (all types) and the tags breast, trialist.
Shares the tags breast, trialist.
Shares the tags breast, trialist.
Shares HER2-positive breast cancer and the tags breast, trialist.
Shares Breast cancer (all types) and the tags breast, trialist.
Shares HER2-positive breast cancer and the tags breast, trialist.
Shares Breast cancer (all types) and the tags breast, trialist.